CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

$40.72 +0.34 (+0.84%)

(As of 12/20/2024 05:51 PM ET)

CRISPR Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 18 Analyst Ratings

Sell
1

Hold
8

Buy
9

Based on 18 Wall Street analysts who have issued ratings for CRISPR Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 1 has given a sell rating, 8 have given a hold rating, and 9 have given a buy rating for CRSP.

Consensus Price Target

$77.93
91.39% Upside

According to the 18 analysts' twelve-month price targets for CRISPR Therapeutics, the average price target is $77.93. The highest price target for CRSP is $105.00, while the lowest price target for CRSP is $48.00. The average price target represents a forecasted upside of 91.39% from the current price of $40.72.

Get the Latest News and Ratings for CRSP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors.

CRSP Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	10 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$77.93	$74.94	$75.63	$68.39
Forecasted Upside	91.39% Upside	56.51% Upside	61.80% Upside	7.41% Upside
Consensus Rating	Hold	Hold	Hold	Hold

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

CRSP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRSP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CRISPR Therapeutics Stock vs. The Competition

Type	CRISPR Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.44	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	91.39% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent CRSP News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/20/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00	+112.98%
12/10/2024	Chardan Capital 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$94.00 ➝ $94.00	+88.60%
11/6/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Sector Perform ➝ Sector Perform	$53.00 ➝ $53.00	+5.98%
11/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$59.00 ➝ $55.00	+9.21%
11/6/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $84.00	+66.80%
8/12/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$120.00 ➝ $100.00	+110.84%
If you see ONE chart today… make it this one (Ad) $1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING. And expects this underappreciated niche to continue rallying well into 2026.
8/8/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral
8/6/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$60.00 ➝ $59.00	+18.81%
8/2/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.00	+64.08%
6/28/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Chattopadhyay Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
6/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $105.00	+71.65%
5/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$89.00 ➝ $84.00	+50.27%
5/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$102.00 ➝ $95.00	+85.19%
5/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $65.00	+24.12%
5/9/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$46.00 ➝ $52.00	-2.42%
3/6/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$82.00 ➝ $99.00	+22.24%
2/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$46.00 ➝ $48.00	-43.64%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
12/11/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$30.00	-53.52%
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$62.00 ➝ $63.00	+30.33%
5/30/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00	+15.99%
5/9/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
4/17/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$75.00	+38.63%
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$44.00	-1.03%
3/17/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+54.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:55 PM ET.

CRSP Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for CRISPR Therapeutics is $77.93, with a high forecast of $105.00 and a low forecast of $48.00.
: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.
: According to analysts, CRISPR Therapeutics's stock has a predicted upside of 91.39% based on their 12-month stock forecasts.
: CRISPR Therapeutics has been rated by research analysts at Barclays, Chardan Capital, JMP Securities, Needham & Company LLC, and Royal Bank of Canada in the past 90 days.
: Analysts like CRISPR Therapeutics less than other "medical" companies. The consensus rating for CRISPR Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CRSP compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

This page (NASDAQ:CRSP) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Stock Forecast & Price Target